AIDSFREE NIGERIA

HIV SELF-TESTING PROJECT REPORT

APRIL 2019
AIDSFree

The Strengthening High Impact Interventions for an AIDS-free Generation (AIDSFree) Project is a five-year cooperative agreement funded by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) with the United States Agency for International Development (USAID) under Cooperative Agreement AID-OAA-A-14-00046. AIDSFree is implemented by JSI Research & Training Institute, Inc. with partners Abt Associates Inc., Elizabeth Glaser Pediatric AIDS Foundation, EnCompass LLC, IMA World Health, the International HIV/AIDS Alliance, Jhpiego Corporation, and PATH. AIDSFree supports and advances implementation of the U.S. President’s Emergency Plan for AIDS Relief by providing capacity development and technical support to USAID missions, host-country governments, and HIV implementers at local, regional, and national levels.

Recommended Citation


JSI Research & Training Institute, Inc.
2733 Crystal Drive, 4th Floor
Arlington, VA 22202 USA
Phone: 703-528-7474
Fax: 703-528-7480
Email: info@aids-free.org
Web: aidsfree.usaid.gov
# CONTENTS

Acronyms ......................................................................................................................................................... vii

Background ....................................................................................................................................................... 1
  The Situation................................................................................................................................................................. 1

Objectives........................................................................................................................................................... 3
  Introduction .................................................................................................................................................................. 3

Findings .............................................................................................................................................................. 5
  Stakeholder Meetings ............................................................................................................................................... 5

Discussion & Recommendations .................................................................................................................. 7

Conclusion ......................................................................................................................................................... 9

References ......................................................................................................................................................... 11


<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIDSFree</td>
<td>Strengthening High Impact Interventions for an AIDS-free Generation</td>
</tr>
<tr>
<td>HIVST</td>
<td>HIV self-testing</td>
</tr>
<tr>
<td>HTS</td>
<td>HIV testing service(s)</td>
</tr>
<tr>
<td>MER</td>
<td>monitoring, evaluation, and research</td>
</tr>
<tr>
<td>NASCP</td>
<td>National AIDS and STI Control Programme</td>
</tr>
<tr>
<td>PEPFAR</td>
<td>U.S. President’s Emergency Plan for AIDS Relief</td>
</tr>
<tr>
<td>PNS</td>
<td>partner notification services</td>
</tr>
<tr>
<td>USAID</td>
<td>United States Agency for International Development</td>
</tr>
</tbody>
</table>
BACKGROUND

The Situation

In December 2016, the World Health Organization, or WHO, released global guidelines recommending assisted partner notification services (PNS) and HIV self-testing (HIVST) as new strategies to reach high-risk and hard-to-reach populations with HIV testing (WHO 2015). HIV self-testing is a process in which a person collects his or her own specimen (oral fluid or blood) and then performs a test and interprets the result, often in a private setting, either alone or with someone he or she trusts. HIV self-testing does not provide a definitive diagnosis; rather, all reactive HIVST results need further testing by a health provider, following the national HIV testing algorithm. HIV self-tests are available in the United States and many countries in Europe, and increasingly throughout sub-Saharan Africa and other parts of the world.

Studies from Kenya, Lesotho, Malawi, Zambia, and Zimbabwe suggest that HIVST is feasible, acceptable, and performed with high-quality when certain conditions are met (Choko 2015, Indravudh 2017, Kurth 2016, Mavedzenge 2017, Sibanda 2017, Zanolini 2017, Zerbe 2015) HIVST can improve program outcomes, including identification of newly diagnosed people living with HIV and linkage with care and treatment (Johnson 2017, Moore 2017). It is cost-effective, and reports of social harms following HIVST are rare (Cambiano 2015, Choko 2015). Policies supporting HIVST exist in at least 12 sub-Saharan African countries to date, and are under development in at least nine more (WHO and Unitaid 2018). In October 2017, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) included a new HIVST indicator in its monitoring, evaluation, and research (MER) guidance for implementing partners (number of HIVST kits distributed), with recommendations for disaggregations and additional data elements for describing and tracking HIVST implementation (PEPFAR 2017). However, HIVST technical and monitoring and evaluation recommendations have not been widely implemented in Nigeria, and although the National HIV Testing Services (HTS) guidelines now reflect this new strategy, the broader National Prevention, Treatment, and Care guidelines do not. In Nigeria, HIVST has not been implemented to scale, and thus questions remain about whether this would be a successful approach for reaching new HIV-positive clients and linking them to care in Nigeria. The government of Nigeria and PEPFAR are working to improve the availability of HIVST products, the process for offering and distributing HIVST kits, and the quality and scale-up of these services in Nigeria.
OBJECTIVES

Introduction

The primary objective of the AIDSFree HIVST technical assistance was to improve policy and implementation resources available for the scale-up of HIVST in Nigeria. The AIDSFree HIVST technical assistance project convened stakeholders to discuss key technical issues in HIVST and provide recommendations for consideration by PEPFAR and the federal Ministry of Health/National AIDS and STI Control Programme (NASCP) for incorporation into the national HIVST guidelines. The primary focus technical area is HIV testing services, which includes linkage to HIV care and treatment.
Findings

Stakeholder Meetings

An initial stakeholder meeting was held in June 2018 at the NASCP facilities. This half-day meeting allowed key stakeholders from donors, regulatory agencies, and implementing partners to discuss key technical issues related to HIVST in Nigeria. Kristina Grabbe (AIDSFree) presented a global status update on HIVST, providing evidence about the benefits and challenges of HIVST implementation worldwide. The meeting included representation from the following agencies:

- Federal Ministry of Health/NASCP
- National Agency for the Control of AIDS
- U.S. Centers for Disease Control and Prevention
- USAID
- U.S. Department of Defense, Walter Reed Project
- UNICEF
- Joint United Nations Programme on HIV/AIDS
- World Health Organization
- Clinton Health Access Initiative
- FHI 360
- Society for Family Health
- World Bank
- AIDS Healthcare Foundation
- AIDSFree
- Jhpiego/Maternal and Child Survival Program

Subsequently, a two-day meeting was held with the national HIV testing services task team to review an initial draft of the operational guidelines for HIVST prepared by Ms. Grabbe in August 2018. This meeting was held in September of 2018. NASCP Head of Prevention (Dr. Deborah Odoh) and National Coordinator (Dr. Sunday Aboje) opened the meeting, acknowledging the importance of HIVST as an additional HIV testing strategy and the opportunity it presents for reaching people who have not yet tested for HIV. Ms. Grabbe presented again on the state of HIVST globally, highlighting current evidence and policy issues arising from work in other countries and Nigeria. Dr. Sylvia Adebajo presented on a Population Council HIVST study with men who have sex with men in Nigeria, indicating OraQuick HIV self-tests are feasible and acceptable among this population. Joy Ogbu, Head of Laboratory, NASCP presented an update on the valuation of HIVST kits in Nigeria, reinforcing that there is currently only one approved HIVST for use in Nigeria (Amethyst) but that other kits are encouraged to undergo evaluation. OraSure Technologies was expected to submit its kit for evaluation in September 2018. Ima John-Dada and Ms. Grabbe presented the draft operational guidelines for HIVST chapter by
chapter, at which point the group broke into smaller groups to review and edit each chapter. At the end of day two, groups presented their edits and recommendations to the larger group and a timeline for completing the guidance (after the completion of the AIDSFree Project) was drafted.
DISCUSSION & RECOMMENDATIONS

The meetings facilitated by AIDSFree provided the opportunity to discuss key technical issues related to HIVST that will be incorporated into national HIVST operational guidance. It is recommended that following these meetings, guidelines be finalized, edited, and reviewed by the task team. The federal Ministry of Health shall host another meeting in November for the task team to adopt the guidelines, and guidelines shall be printed in January 2019 and disseminated nationwide.
CONCLUSION

The work completed under this AIDSFree program helped to initiate the development of national HIVST guidelines, bringing Nigeria into the fold of countries that have updated policy recommendations to recommend this innovative approach to case finding. Having a policy in support of HIVST will allow Nigeria to advance HIVST kit evaluation and approval and get more high-quality HIVST products on the market. The policy will also allow implementing partners to begin offering HIVST, and will outline standards to ensure high-quality service delivery.
REFERENCES


https://doi.org/10.1089/AID.2017.0156.

HIV Self-Testing Technical Considerations

Kristina Grabbe and Michelle Willcox
NASCP Conference Room, Abuja
June 22, 2018
Jhpiego/MCSP/AIDSFree
Objectives

• Review experiences and lessons learned with HIVST in multiple countries to date
• Identify priorities for HIVST implementation in Nigeria
• Outline donor and partner plans for HIVST support in Nigeria
Countries with Operational Guidelines and Implementation Materials

- Kenya
- Malawi
- South Africa
- Tanzania
WHO Guidance on HIV ST and PNS

- Original guidance 2015
- Updated guidance 2016
- Aims:
  - Support implementation & scale-up
  - Provide guidance on testing approach integration into HTS at community and facility levels
  - Support introduction of HIVST as a formal HTS intervention using quality-assured, locally and internationally approved products
  - Show new HTS approaches can contribute to closing the testing gap
HIV self-testing should be offered as an additional approach to HIV testing services (strong recommendation, moderate quality evidence)
Kenya Operational Guidance on HIV ST

- Original guidance 2015
- HIV ST included as an approach within HIV Testing Services
- Specific guidance included on use of self-testing to increase access to knowledge of HIV status in Kenya
Kenya Journey to HIVST Roll Out

- HIVST first included in the national guidelines since 2009, but took 7 years for it be implemented
- 7 years of formative research on HIVST
  - 72% of respondents in last KAIS 2012 indicated that they would be willing to use a self test kit
  - Acceptability: 99% returned for confirmatory testing
  - Found a higher proportion of undiagnosed infection
  - 83% started ART on day of confirmation
  - Packaging
  - Social harms
Progress in Kenya Towards Adoption of HIVST

- Inclusion in Kenya HIV Testing Guidelines 2015
- HIV Self Testing operational manual develop
- HIV Self testing to be launched together with PrEP at end of April
- Three HIV Self test kits registered in country by Pharmacy and Poisons Board
- Lab board listing ongoing
- Resource mobilization through PEPFAR, Global Fund and UNITAID
Evidence on HIVST

• High uptake of self-testing has been reported among health care workers
• High uptake of HIVST specifically reported among youth, men and those who had not tested before
• Benefits: First time testers, privacy, convenience, reduced stigma
• Pharmacies identified as point of distribution
• Need to address pre-test information/counseling
• There is no significant harm associated with HIVST
What is HIV Self-Testing (HIVST)?

Reactive results need confirmation by trained tester using a validated national algorithm.
Guiding Principles for HIVST: 5Cs

• Consent
• Counseling
• Confidentiality
• Correct Test Results
• Connection
Delivery Approaches

- **Unassisted HIVST**: Individual obtains an HIVST kit and performs the HIV test following the instructions in the package insert.

- **Directly assisted HIVST**: Individual performing HIVST receives in-person demonstration from a trained provider or peer before or during HIVST, including instructions on how to perform self-test and interpret the result.
  - This assistance is provided in addition to the manufacturer supplied instructions for use and other materials found inside HIVST kits.
  - May be observed or unobserved.
Distribution Channels

• Open access
  • Pharmacies, Internet, Private Providers

• Community-based
  • CHW, Peer Educators, VCT

• Facility-based
  • PITC, ANC, Kiosks
HIVST DISTRIBUTION MODELS

Open Access
- Pharmacies, chemists
- Internet, social media
- Vending machines
- Private providers

Community-based
- PE, CHW, Outreach
- Workplaces
- Colleges and Universities
- VCT

Facility-based
- Integrated with PITC
- Kiosks
- Through ANC and PLHIV
- Integrated with KP services (including PrEP) and VMMC

Directly Assisted
- Trained distributor provides brief demonstration, gives information
- Can observe or provide assistance during self-testing (optional)
- Instruction-for-use included in kit

Unassisted
Instructions-for-use included in the kit:
- Pictorial/written
- Include a link to a video and/or hotline number
- Multimedia instructions (tablet)
- Remote support via SMS, QR code, or mobile messaging applications
- Package insert included in the kit
Target Populations

• General Population
  • Partners of PLHIV, including male partners of women in PMTCT (PNS)
  • Men
  • Adolescents and/or Children

• Key Populations
  • FSW
  • MSM
  • PWID
Definitions: HIVST Providers

- **Service provider:** In the context of HIVST is an organization, business or individual which offers service to others either in exchange for payment or for free.

- **Vendor:** In the context of HIVST is an outlet which sells directly to the consumer e.g. chemists.

- **Distributor:** An agent who supplies HIVST kits to stores and other businesses that sell to consumers e.g. wholesale.
HIVST Algorithm

Perform HIV self-test
A0

A0 +
Report reactive HIV test
Advise linkage to further HIV testing for diagnosis
If confirmed HIV-positive, refer for treatment

A0 −
Report HIV-negative
Recommend retesting as needed
Advise linkage to relevant HIV prevention services

A0 = Assay 0 (test for triage)
Interpreting HIVST Results

- **Reactive results:** HIV antibodies are present in the blood or oral fluid sample.
  - Anyone with a reactive HIVST result must have their test confirmed by additional HTS by a trained provider following the national HIV testing algorithm.

- **Non-reactive results:** HIV antibodies were not found in the blood or oral fluid sample.
  - Anyone with a non-reactive HIVST result does not need further testing but should be supported to re-test if they have had a recent potential HIV exposure or are at on-going HIV risk.
<table>
<thead>
<tr>
<th>Test Kit Name</th>
<th>Specimen</th>
<th>Approval Status</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atomo HIV Self-Test</td>
<td>Whole Blood</td>
<td>GF ERPD</td>
<td>On request</td>
<td>On request</td>
</tr>
<tr>
<td>INSTI HIV Self Test</td>
<td>Whole Blood</td>
<td>GF ERPD</td>
<td>On request</td>
<td>On request</td>
</tr>
<tr>
<td>Biosure HIV Self Test</td>
<td>Whole Blood</td>
<td>GF ERPD</td>
<td>On request</td>
<td>On request</td>
</tr>
<tr>
<td>SURE CHECK HIV Self-Test</td>
<td>Whole Blood</td>
<td>GF ERPD</td>
<td>On request</td>
<td>On request</td>
</tr>
<tr>
<td>OraQuick HIV Self-Test</td>
<td>Oral Fluid</td>
<td>WHO PQ</td>
<td>99.02%</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

*With approval from a founding member of the GHTF. All information is provided by manufacturers (UNITAID/WHO Landscape July 2016/Dec 2016)
OraQuick HIV Self-Test

Jhpiego/AIDSFree Technical Assistance

- Support development of operational resource package for HIVST
  - Operational Guidelines
  - Job Aids and Implementation Materials
  - IEC/Promotional Materials
  - Required Indicators
  - Process/Recommended Program Indicators
  - Data Collection and Reporting Tools
For more information, please visit
www.mcsprogram.org

This presentation was made possible by the generous support of the American people through the United States Agency for International Development (USAID), under the terms of the Cooperative Agreement AID-OAA-A-14-00028. The contents are the responsibility of the authors and do not necessarily reflect the views of USAID or the United States Government.

facebook.com/MCSPglobal
twitter.com/MCSPglobal
Understanding the Market Based Challenges and Opportunities for HIV ST
Market Constraints Globally (PSI, 2016)

1. Lack of demand for quality-assured HIVST translating into concrete purchase orders
2. Price pressure from donors and governments
3. Lack of incentives to innovate for further product development
4. Fragmented and uncertain regulatory environment for manufacturers
5. Lack of ownership of and investment in key market functions
Relevant Recommendations from Global Market Analysis (PSI, 2016)

• Engage a market manager to help the market actively evolve from operational research studies to concrete demand and market development at scale
  • Coordination and advocacy
  • Go-to-market strategic planning
  • Regulatory support and guidance
  • Collection of market intelligence

• Conduct demonstration projects to understand the potential of specific distribution channels, especially through the private sector
Total Market Approach

- TMA framework for developing and facilitating markets in improving efficiency and access for a specific product
  - Identification of all market players for service and product
  - Market segment identification and targeted strategies
  - Involvement of public and private (not-for-profit and for-profit) sectors
  - Programs and policies enhance the market and remain client-focused
Total Market Approach (K4Health)
Total Market Approach (Palladium Group)

Our TMA Framework

Palladium’s TMA framework (Figure 1) is designed to capture the complex process of market analysis, multi-sectoral engagement, market-shaping interventions, and market monitoring relevant to TMA, while recognizing that not all components would be applied in all situations. As learning around TMA implementation evolves, so does the Palladium framework. TMA is an intensive, iterative process—but one that leads to important results. As described below, the six elements are closely linked, often overlapping, and will vary depending on the country context.
Guiding Questions for TMA

• Are we maximizing participation of all service provision actors?
• What populations are currently served and where?
• What types of service delivery approaches can each do best for each segment?
• How can we grow the whole market?
ANNEX 2. SEPTEMBER 2018 HIV SELF-TESTING: THE GLOBAL LANDSCAPE PRESENTATION
HIV Self-Testing: the Global Landscape

Presentation to Nigeria HIV Testing Services Task Team
September 6, 2018
Kristina L. Grabbe, Jhpiego/MCSP/AIDSFree
Setting the Stage: The ‘First 90’
Progress toward the 90-90-90, 2015-2017

9.4 million people living with HIV (PLHIV) remain undiagnosed

Source: UNAIDS 2018; C Johnson AIDS 2018
Many of those unreached are key populations

*Proportion of key populations diagnosed and/or on treatment compared to general populations, by country*

Special analysis using UNAIDS Global AIDS Monitoring data vs available key population data (data published in peer reviewed journals and IBBS) matched for year; C Johnson AIDS 2018
Many of those unreached are young people

In 2017 there were 1.8 million new HIV infections in people 37% were among 15-24 year olds – most in southern Africa

Majority of new HIV infections among young men, compared to women, outside Africa

Source: WHO/UNAIDS 2018; C Johnson AIDS 2018
Many of those unreached are men

Proportion of people with HIV who know their status, by sex
20 reporting African countries, 2017

“Despite higher disease burden among women, more men living with HIV are dying”

Source: WHO/UNAIDS 2018; C Johnson AIDS 2018
Newly released population-based surveys indicate decreased incidence and progress towards 90-90-90 but reinforce the need for differentiated models of service delivery targeting unreached populations, with particular emphasis on ‘First 90’ and reaching men.

Source: https://phia.icap.columbia.edu/; HSRC AIDS 2018
Nigeria Progress to 90-90-90

- 38% PLHIV know their HIV status (49% women, 29% men)
- 1 million PLHIV are on treatment (44% women LIVH, 22% men LIVH)
- Viral suppression estimates unknown
- Regional and population disparities
Innovation is needed to close this gap

Find the 62% of PLHIV in Nigeria who don’t know their status

Link the 67% of PLHIV in Nigeria who are not on ART

Link HIV-negatives to effective prevention to stay negative!

What got us here, won’t get us there.

Photo Credit: http://fr.ubergizmo.com/2013/02/15/wifi-gratuit-metro-londonien-fin.html
International Guidance on HIVST
HIV Self-testing Recommendation
(WHO, Dec 2016)

HIV self-testing should be offered as an additional approach to HIV testing services (strong recommendation, moderate quality evidence)
What is HIV Self-Testing (HIVST)?

Collects
Performs
Interprets

Reactive results need confirmation by trained tester using a validated national algorithm
HIV self-testing: an important innovation

*Individual collecting their specimen (oral or blood), performing a rapid test and interpreting their result often in private or with someone they trust*

**Key evidence showed HIVST is:**
- Safe and accurate
- Highly acceptable
- Increased access
- Increased uptake and frequency of HIV testing among those at high risk and who may not test otherwise (men, KP, young people, partners of PLHIV)

**WHO recommendation:**
HIV self-testing should be offered as an additional approach to HIV testing services

*(strong recommendation, moderate quality evidence)*

Many different models – ranging from community-based, facility-based, partner-delivered, social network-based, pharmacies, workplace depending on context and who you are trying to reach

*Source: WHO 2016*
WHO HIVST Strategy: “Test for Triage”

- HIVST does not provide a definitive HIV-positive diagnosis.
- HIV self-testers with a reactive (positive) result to receive further testing from a trained provider using a validated national testing algorithm.
- HIV self-testers with a non-reactive test result should retest if they might have been exposed to HIV in the preceding six weeks, or are at high ongoing HIV risk.
- Any person who is uncertain about their HIV self-test result should access facility- or community-based HIV testing.
- HIVST is not recommended for people taking anti-retroviral drugs, as this may cause a false non-reactive result.

Source: WHO 2016
Strategic Planning HIVST Service Delivery

- There are many possible public and private sector HIVST approaches.
- Programmes should evaluate existing HTS approaches to determine where and how to implement HIVST, so that it is complementary and addresses gaps in current coverage.
- Aim to reach untested populations: men, KP, young people, partners of PLHIV.

Source: WHO 2016
Global Policy and HIVST Implementation

• HIVST is an acceptable, safe, accurate, and effective way to reach people who are at risk and may not otherwise test.
• 59 countries now have policies supporting HIVST.
  • Additional 53 countries are developing policies on HIVST, many of which will be completed in 2018.
• Despite rapid policy development, implementation of HIVST is limited to 28 countries worldwide, increased from 13 in July, 2017.
• About 2/3 (18) of countries implementing HIVST are upper middle or high-income countries.

Source: UNITAID 2018
HIVST Implementation
Linkage following HIVST

• Evidence suggests linkage to additional testing to confirm HIV status and treatment initiation following reactive self-test results can be at least equivalent to national linkage rates.
• HIV self-testing can also facilitate linkage to other prevention services, such as preexposure prophylaxis (PrEP).
• Support tools and innovative technologies, such as smartphone apps and a hotline, may also improve linkages to prevention and care after self-testing.
Monitoring and Evaluation for HIVST

• Ensure HIVST is:
  • Reaching the right people (i.e. target populations), and
  • Facilitating access to confirmatory testing and ART for persons who test HIV-positive

• HIV self-test distribution is easy to track, but HIV self-test use and linkage to ART requires follow-up
  • Proactive, community-based follow up (in-person, via phone, text, social messaging)
  • Home-based treatment assessment and initiation
  • Brochures and flyers distributed together with HIV self-tests
  • Telephone hotlines
  • Internet and computer-based programs and applications
  • Vouchers, coupons, or rebates
  • Appointment cards and referral slips
Monitoring Impact of HIVST Over Time

- HIVST is private and discreet, makes it difficult to collect information on effectiveness of HIVST programs, but monitoring is important!
- Possible tools for monitoring and tracking HIVST include:
  - Monitor and analyze calls to HIV self-test hotlines and messaging services, including pictures of test results
  - Add question(s) to population-based surveys (DHS, AIS, PHIA)
  - Modify site-level and facility-level logbooks and testing registers to include HIVST, i.e. “Have you ever used an HIV self-test before?”
  - Internet and mobile phone surveys and tools for clients to report experiences using HIV self-tests
  - Focused follow-up with target populations
  - Implementation evaluation and studies to track HTS coverage and enrollment on ART for hard-to-reach populations
  - Financial or in-kind incentives to encourage users to report on their HIVST experiences
Case Example: Namibia

• 2018 Namibia endorsed HIVST in national guidelines and developed SOPs
• Peers from KP groups were trained to distribute self-tests
• Manufacturer instructions for use were provided in 4 local languages
• Peers provided demonstrations and issued HIV self-tests to FSW in their communities
  • FSW could receive 2 kits to encourage partner testing
  • Peer distributors helped link people to further testing, treatment, and prevention services (including PrEP)

Source: Taimi Amaambo, Society for Family Health, Denis Mali, USAID
Namibia: Results

• Between March and May 2018, peer distributors gave out 1,475 kits
• 813 recipients disclosed their test results to peer distributors
  • 24 (2.9%) were HIV-positive
  • 23 (96%) were linked to treatment
  • 62 (8%) of those who were confirmed HIV-negative were linked to PrEP services

Source: Taimi Amaambo, Society for Family Health, Denis Mali, USAID
Lessons from Kenya shift from VCT to HIVST

1. We have to start and learn as we go along! – don’t let fears get in the way of progress
2. The most invested (policy makers, providers) are sometimes the barriers
3. We have to trust that people will do what is best for them when they have accurate information, technology, and are motivated
4. We must actively focus on couples/partners
5. We need an open and saturated market - relinquish some control of distribution models and points, leverage other sectors
6. We need to invest in systems:
   • Regulation, evaluation, approval
   • Forecasting and quantifications
   • Commodity supply and management systems
   • Data collection and collation
Current Evidence
Priority Area: HIV Self-Testing

- Secondary HIVST distribution to male partners of young women leads to increased male partner and couples testing, no increased risk of IPV
  - Agot et al, Kenya
- Community Based Distribution Agents effectively delivered HIVST in Malawi, leading to increased coverage of HIVST in rural populations
  - Indravudh et al, Malawi
- Persons at risk for any adverse event following HIVST are those with prior history of violence in relationship
  - Cowan et al, Zimbabwe
- Blood-based HIVST is feasible and acceptable for semi-supervised HIVST
  - Cowan et al, Zimbabwe and Malawi

Aim

To evaluate feasibility and acceptability of HIVST with blood based RDTs in Malawi and Zimbabwe.

Methodology

- Mixed-methods study observing the distribution and use of BB and OF self-test kits at rural and urban primary health centres / HIV testing sites.
Global Market for HIVST
Unitaid/WHO: Market and technology landscape, 4th edition
The Global Market

- Procurement forecast suggests significant growth for HIVST in both public and private sectors beyond 2020.
- Volumes are expected to grow from 1 million tests globally in 2017 to an estimated 16.4 million tests by the end of 2020.
  - Public sector is expected to contribute around 9.1 million.
  - Private sector is expected to account for remaining 7.3 million.

Source: UNITAID 2018
HIV Self-test Diagnostics

• As of July 2018, 8 HIVST (2 oral fluid, 6 blood-based) have received some degree of international approval
  • Either prequalified by WHO, approved by a regulatory authority/International Medical Device Regulators Forum, or recommended for procurement by Unitaid/Global Fund Expert Review Panel for Diagnostics.

• Only 1 HIV self-test, an oral fluid test, has been prequalified by WHO.

• Locally manufactured HIV self-test kits with national-level approval in some countries (6 products identified), including Belarus, Brazil, and Nigeria, but quality and performance of these kits vary.

• There are at least 6 other HIV self-tests under development – 3 use whole blood specimens, 2 use oral fluid specimens, and 1 uses urine specimens.

Source: UNITAID 2018
HIV self-test kits with international approval (WHO PQ, approved by regulatory authority in one of founding member countries of International Medical Device Regulators Forum, or eligible for procurement on recommendation of Unitaid/GF ERPD)

<table>
<thead>
<tr>
<th>Test name (manufacturer/supplier)</th>
<th>Test generation</th>
<th>Specimen</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Approval status</th>
<th>Markets</th>
<th>Price in US$ per test</th>
</tr>
</thead>
<tbody>
<tr>
<td>atomo HIV Self Test (Atomo Diagnostics, Australia)</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt;</td>
<td>Wholeblood</td>
<td>99.7%</td>
<td>99.7%</td>
<td>CE mark, ERPD (Category-3)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Kenya, South Africa</td>
<td>Public sector: $ 3 (depends on volume)</td>
</tr>
<tr>
<td>autotest VIH&lt;sup&gt;h&lt;/sup&gt; (three packaging formats) (AAZ Labs, France)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt;</td>
<td>Wholeblood</td>
<td>100.0%</td>
<td>99.8%</td>
<td>CE mark</td>
<td>Registered and available in 15 European countries&lt;sup&gt;c&lt;/sup&gt;</td>
<td>HIC retail: $ 20–28 Distributors/NGOs: $ 8–15 (depends on packaging format)</td>
</tr>
<tr>
<td>BiosURE HIV Self Test (hard case &amp; soft case) (BioSURE, United Kingdom Ltd)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt;</td>
<td>Wholeblood</td>
<td>99.7%</td>
<td>99.9%</td>
<td>CE mark, ERPD (Category-3)&lt;sup&gt;e&lt;/sup&gt;</td>
<td>South Africa, United Kingdom</td>
<td>HIC retail: $ 42–48 HIC public sector: $ 7.50–15 LMIC retail: $ 11.75</td>
</tr>
<tr>
<td>Exacto&lt;sup&gt;h&lt;/sup&gt; Test HIV (Biosynex, France)</td>
<td>3&lt;sup&gt;rd&lt;/sup&gt;</td>
<td>Wholeblood</td>
<td>99.99%</td>
<td>99.50%</td>
<td>CE mark</td>
<td>Europe&lt;sup&gt;f&lt;/sup&gt;</td>
<td>Not available</td>
</tr>
<tr>
<td>INSTI&lt;sup&gt;i&lt;/sup&gt; HIV Self Test (box &amp; pouch) (bioLytical Labs., Canada)&lt;sup&gt;g&lt;/sup&gt;</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt;</td>
<td>Wholeblood</td>
<td>Box: 100.0% Pouch: 99.8%</td>
<td>Box: 99.8% Pouch:99.5%</td>
<td>CE mark, ERPD (Category-3)&lt;sup&gt;j&lt;/sup&gt;</td>
<td>Several countries in Europe, Nigeria</td>
<td>Price: $ 3–12 MSRP: $ 7–36 (Prices depend on packaging format, volumes and market region)</td>
</tr>
<tr>
<td>OraQuick&lt;sup&gt;®&lt;/sup&gt; In-Home HIV Test (OraSure Technologies, USA)</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt;</td>
<td>Oral fluid</td>
<td>FDA: 91.7% CE: 100.0%</td>
<td>FDA: 99.98% CE: 99.8%</td>
<td>FDA, CE mark</td>
<td>USA</td>
<td>HIC retail: $ 40 Public sector prices vary. Not yet marketed in Europe</td>
</tr>
<tr>
<td>OraQuick&lt;sup&gt;®&lt;/sup&gt; HIV Self Test (OraSure Technologies, USA)</td>
<td>Not available&lt;sup&gt;l&lt;/sup&gt;</td>
<td>Oral fluid</td>
<td>99.4%</td>
<td>99.0%</td>
<td>WHO PQ&lt;sup&gt;®&lt;/sup&gt;</td>
<td>Burundi, Kenya, South Africa, Uganda, Zambia, Zimbabwe</td>
<td>LMIC ex-works&lt;sup&gt;®&lt;/sup&gt;: $ 2 for 50 countries&lt;sup&gt;l&lt;/sup&gt;</td>
</tr>
<tr>
<td>SURE CHECK&lt;sup&gt;®&lt;/sup&gt; HIV Self Test (Chembio Diagnostic Systems Inc., USA)</td>
<td>2&lt;sup&gt;nd&lt;/sup&gt;</td>
<td>Wholeblood</td>
<td>Not available</td>
<td>Not available</td>
<td>ERPD (Category-3)&lt;sup&gt;k&lt;/sup&gt;</td>
<td>Not available</td>
<td>Not available</td>
</tr>
</tbody>
</table>
HIV self-test kits with national-level approval in selected countries

<table>
<thead>
<tr>
<th>Test name (manufacturer/supplier)</th>
<th>Specimen</th>
<th>Approval status</th>
<th>Availability</th>
<th>Price in US$</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Action!</strong> (Orangelife Comércio e Indústria LTDA, Brazil)</td>
<td>Whole blood</td>
<td>ANVISA, Brazil (National Health Surveillance Agency)</td>
<td>Brazil</td>
<td>Free-on-board*: $ 9.80</td>
</tr>
<tr>
<td><strong>Alerta</strong> (Wama Diagnóstica, Brazil)</td>
<td>Whole blood</td>
<td>ANVISA, Brazil (National Health Surveillance Agency)</td>
<td>Brazil</td>
<td>Not available</td>
</tr>
<tr>
<td><strong>Amethyst HIV 1&amp;2 Test Kit</strong> (Bedford Biotech Nigeria Ltd., Nigeria)</td>
<td>Oral fluid</td>
<td>Approved in Nigeria</td>
<td>Nigeria</td>
<td>$ 14 recommended market price. Prices for public sector and NGOs may vary.</td>
</tr>
<tr>
<td><strong>HIV Detect</strong> (Eco diagnóstica, Brazil)</td>
<td>Oral fluid</td>
<td>ANVISA, Brazil (National Health Surveillance Agency)</td>
<td>Brazil</td>
<td>Not available</td>
</tr>
<tr>
<td><strong>Sali teste</strong> (Ebram Produtos Laboratoriais, Brazil)</td>
<td>Oral fluid</td>
<td>ANVISA, Brazil (National Health Surveillance Agency)</td>
<td>Brazil</td>
<td>Not available</td>
</tr>
<tr>
<td><strong>Unnamed test</strong> (Belarus)</td>
<td>Not available</td>
<td>Manufactured and approved in Belarus</td>
<td>Belarus</td>
<td>Not available</td>
</tr>
</tbody>
</table>
HIV self-test kits under development

<table>
<thead>
<tr>
<th>Test name (manufacturer/supplier)</th>
<th>Specimen</th>
<th>Plan for regulatory approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asanté™ HIV Self Test</td>
<td>Oral fluid (also, a version is under development that can test either an oral fluid or whole blood specimen in a single device)</td>
<td>Not available</td>
</tr>
<tr>
<td>AwareTM HIV-1/2 OMT Oral HIV Self Test</td>
<td>Oral fluid</td>
<td>Plan to apply for WHO PQ and CE mark</td>
</tr>
<tr>
<td>First Response HIV 1-2.0 Card Test (Self Test)</td>
<td>Whole blood</td>
<td>Plan to apply for WHO PQ</td>
</tr>
<tr>
<td>To be named</td>
<td>Whole blood</td>
<td>Not available</td>
</tr>
<tr>
<td>To be named</td>
<td>Urine</td>
<td>National regulatory approval in China pending</td>
</tr>
<tr>
<td>To be named</td>
<td>Whole blood</td>
<td>Not available</td>
</tr>
</tbody>
</table>

(China)
Future directions for HIVST diagnostics

- Improve existing technologies through open market and increased competition
- Optimize and improve self-test product performance
  - Simplify sample collection, clear instructions, demonstrations and support tools, fewer steps, faster and easy to read results
- Multiplex self-tests with ability to test simultaneously for more than one disease using a single specimen and one test procedure or test run
  - Possible combinations include HIV, syphilis, hepatitis B and C, among others
- Self-testing for STIs
  - Self-collection systems exist for certain STIs, but no approved self-test currently
Cost of HIV self-tests

• Price of HIVST kits with WHO PQ or stringent regulatory authority varies considerably, depending on setting, market sector, and product packaging.
  • High income countries, private sector prices range from $20 to $48 per test; public sector NGO procurement range from $7.5 to 15 per test.
  • In LMIC self-tests are available at a lower price, ranging from $2 to $12 per test in public sector, and $7 to 12 per test in private sector.
  • Lowest price per test ($2) is available in public sector in 50 high-burden LMIC settings, including Nigeria, for a limited time through an agreement between BMGF and the manufacturer of the only WHO PQ’d self-test.

Source: UNITAID 2018
Public Sector Financing and Procurement

- Depending on funding source and procurement method, process for financing, procurement, and delivery of HIV self-tests can be complex and time consuming.
- Financing through Global Fund – estimated time from grant evaluation to estimated procurement date is 503 days.
  - Does not include time required to prepare grant submission.
- Global Health Supply Chain (GHSC) is main procurement agent for PEPFAR/USAID.
  - Average lead-time to process and deliver HIV self-tests is 115 days across 21 countries in 2017 and 2018.
Public Sector Forecasting

• Moderate forecast assumes countries scaling up HIVST achieve self-test volumes of 2.5% to 5% of total RDT volumes
• Aggressive forecast scenario assumes a range of 5% to 7.5%.
• This proportion may increase over time, but HIV self-tests will likely remain a small fraction of all HIV RDTs even by 2020.
  • In 5 key countries (Kenya, Malawi, South Africa, Zambia, Zimbabwe) public sector moderate forecast is 18.8% of RDT volumes in 2020.
Challenges with HIVST Scale-up

- Consumer choices and market competition is limited, due to only one WHO PQ’d self-test
  - In Nigeria, only one nationally approved test, not WHO PQ’d
- Lack of clarity, or absence of national regulatory pathways in some settings hinders market entry for new products
  - Registration processes can be lengthy or expensive, or may allow substandard products to enter market
- Awareness of HIVST remains low in target populations in many settings
  - Large-scale promotion campaigns are needed to generate and sustain demand

Source: UNITAID 2018
HIVST User Preferences

• Privacy, convenience, and immediacy of results are appealing
• Cost and accuracy drive demand.
  • In Zambia, adults and adolescents indicated a willingness to pay for HIV self-tests.
    • Those who had tested in last 12 months were willing to pay ~$3.30 for a self-test kit.
    • Those who had not tested recently were willing to pay ~$4.60.
• Specimen type – oral fluid or blood – does not seem to have major influence on choice, but some population groups may prefer one over the other (MSM, FSW, PWID).
  • Diversifying choice and specimen types will make testing more accessible and appealing and strengthen security of supply.
For more information, please visit
www.mcsprogram.org

This presentation was made possible by the generous support of the American people through the United States Agency for International Development (USAID), under the terms of the Cooperative Agreement AID-OAA-A-14-00028. The contents are the responsibility of the authors and do not necessarily reflect the views of USAID or the United States Government.